
Please try another search
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Name | Age | Since | Title |
---|---|---|---|
Orville G. Kolterman | 77 | - | Member of Scientific Advisory Board |
W. Kenneth Ward | - | - | Member of Scientific Advisory Board |
Marla S. Persky | 69 | 2021 | Independent Chairman |
John P. Shannon | 63 | 2021 | CEO & Director |
John H. Johnson | 67 | 2021 | Independent Non-Executive Director |
Morey W. Haymond | - | - | Scientific Advisory Board Member |
John L. Brooks | 74 | - | Scientific Advisory Board Member |
Jeffrey W. Sherman | 70 | 2021 | Independent Director |
Garheng Kong | 50 | 2021 | Independent Non-Executive Director |
Dawn Halkuff | 54 | 2021 | Independent Director |
James Brady | 63 | 2025 | Independent Director |
Barbar-Jean Anne Bormann-Kennedy | 66 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review